Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 4/20 | 0.73 |
| ▸ | DRD2 | P14416 | 2/20 | 0.73 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.73 |
| ▸ | HTR3B | O95264 | 2/20 | 0.73 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.73 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.73 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | DRD3 | P35462 | 1/20 | 0.73 |
| ▸ | HTR6 | P50406 | 1/20 | 0.73 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | HTR1A | P08908 | 4/20 | 0.68 |
| ▸ | HTR7 | P34969 | 4/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29786229 | 1.00 | HTR3A (0.73) | HTR3ADRD2HTR3EHTR3BHTR3D | |
| SCHEMBL27261438 | 0.85 | ADRB1 (0.57) | HTR3ADRD2HTR3EHTR3BHTR3D | |
| SCHEMBL8109063 | 0.85 | HTR3A (0.60) | HTR3ADRD2HTR3EHTR3BHTR3D | |
| SCHEMBL379 | 0.84 | HTR3A (1.00) | HTR3ADRD2HTR3EHTR3BHTR3D | |
| SCHEMBL29396943 | 0.84 | HTR3A (1.00) | HTR3ADRD2HTR3EHTR3BHTR3D | |
| SCHEMBL7310094 | 0.84 | KMT2A (0.54) | HTR3ADRD2HTR3EHTR3BHTR3D | |
| SCHEMBL6366499 | 0.84 | HTR3A (1.00) | HTR3ADRD2HTR3EHTR3BHTR3D | |
| SCHEMBL31348240 | 0.83 | ADRB1 (0.65) | HTR3ADRD2HTR3EHTR3BHTR3D | |
| SCHEMBL5372329 | 0.83 | HTR6 (0.73) | HTR3ADRD2HTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL6602545 | 0.83 | LMNA (1.00) | HTR3ADRD2HTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111377846-B | Piperazine benzamide derivative and application thereof | 江苏恩华药业股份有限公司 | 2022-05-24 | — | — | CN | disclosed |
| CN-111377846-A | Piperazine benzamide derivative and application thereof | 江苏恩华药业股份有限公司 | 2020-07-07 | — | — | CN | disclosed |
| CN-100422181-C | [1,8] naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER LAMBERT CO (US) | 2008-10-01 | — | — | CN | disclosed |
| US-7160888-B2 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER LAMBERT COMPANY LLC (US) | 2007-01-09 | — | — | US | disclosed |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| CN-1839134-A | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER LAMBERT CO (US) | 2006-09-27 | — | — | CN | disclosed |
| EP-1660497-A1 | [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019215-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2005-02-24 | — | — | US | disclosed |
| CN-1392140-A | Organic compound with bis-4-dicyanomethylene pyran ring and synthetic method and application thereof | PHYSICAL & CHEMICAL TECHNOLOGY (CN) | 2003-01-22 | — | — | CN | disclosed |
| US-5789412-A | 5-HYDROXYTRYPTAMINE (SEROTONIN) RECEPTOR ANTAGONISTS FOR THE CURATIVE OR PREVENTIVE TREATMENT OF PAIN, DEPRESSION, OBSESSIVE COMPULSIVE DISORDERS, ANXIETY OR PANIC ATTACK, OR CANCER | PIERRE FABRE MEDICAMENT (FR) | 1998-08-04 | — | — | US | disclosed |
| EP-0850222-A1 | PIPERAZINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Samjin Pharmaceutical Co., Ltd. (KR) | 1998-07-01 | — | — | EP | disclosed |
| WO-1998000402-A1 | PIPERAZINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 1998-01-08 | — | — | WO | disclosed |
| EP-0773937-A1 | NOVEL ARYL PIPERAZINE-DERIVED PIPERAZIDE DERIVATIVES, METHODS FOR THEIR PREPARATION, THEIR USE AS DRUGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | PIERRE FABRE MEDICAMENT (FR) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996002525-A1 | NOVEL ARYL PIPERAZINE-DERIVED PIPERAZIDE DERIVATIVES, METHODS FOR THEIR PREPARATION, THEIR USE AS DRUGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | PIERRE FABRE MEDICAMENT (FR) | 1996-02-01 | — | — | WO | disclosed |
| EP-0527081-B1 | Substituted 3-piperazinylalkyl-2,3-dihydro-4H-1,3-benzoxazine-4-ones, their preparation and their therapeutical use | PF MEDICAMENT (FR) | 1996-01-03 | — | — | EP | disclosed |
| EP-0527081-A1 | Substituted 3-piperazinylalkyl-2,3-dihydro-4H-1,3-benzoxazine-4-ones, their preparation and their therapeutical use | PIERRE FABRE MEDICAMENT (FR) | 1993-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | DRD1, DRD2, DRD3 | HTR3A 1159/4885DRD2 2/4885HTR3E 1510/4885 |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | HTR3A 1159/4885DRD2 2/4885HTR3E 1510/4885 |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | HTR3A 1159/4885DRD2 2/4885HTR3E 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.